Epigenetics pioneer C. David Allis, PhD, will be awarded the 2014 Japan Prize in Life Sciences in April. The Japan Prize Foundation bestows the prize, worth about $500,000, annually to scientists and researchers who have made substantial contributions to their field and to “the peace and prosperity of mankind.” Allis discovered that histone proteins are chemically modified in order to activate or silence nearby genes. He is a professor at The Rockefeller University in New York, NY.
Hervé Hoppenot, former president of Novartis Oncology, has been named president and CEO of Incyte (Wilmington, DE), which develops small-molecule drugs for oncology and inflammation. At Novartis, Hoppenot was responsible for translational medicine, development, and approval and commercialization, which included $11 billion in global sales. He also helped introduce new indications for Afinitor (everolimus) and Tasigna (nilotinib), and launched two new drugs, Signifor (pasireotide) for Cushing's disease and the JAK inhibitor Jakavi (ruxolitinib) for myelofibrosis.
Roche has promoted Sandra Horning, MD, to chief medical officer and head of global product development. Most recently, she served as head of clinical development for the company's oncology and hematology business and helped shepherd several cancer drugs through development, including Zelboraf (vemurafenib), Erivedge (vismodegib), and Perjeta (pertuzumab). Before joining Roche in 2009, Horning worked as a practicing oncologist, clinical investigator, and professor of medicine at Stanford University School of Medicine in Palo Alto, CA.
For more news on cancer research, visit Cancer Discovery online at http://CDnews.aacrjournals.org.
RSS Feeds